ERBB2 and neoplasm: RC48 is an innovative ADC drug conjugated with a microtubule inhibitor (monomethyl auristatin E) via a cleavable linker, which directly and potently kills HER2-expressing tumor cells, and at the same time has a bystander effect on heterogeneous tumor cells [10].